NASDAQ:CLLS Cellectis (CLLS) Stock Price, News & Analysis $1.98 0.00 (0.00%) (As of 11/13/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Cellectis Stock (NASDAQ:CLLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cellectis alerts:Sign Up Key Stats Today's Range$1.91▼$2.0050-Day Range$1.75▼$2.4052-Week Range$1.70▼$3.77Volume33,706 shsAverage Volume50,188 shsMarket Capitalization$110.06 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Read More… Is Your 401(k) Safe? The Real Risk No One Sees Coming (Ad)Every day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopping, and the digital dollar is coming. You can protect yourself—but only if you act now. Don't wake up too late. Get your Digital Dollar Protection today and secure your retirement before the window closes.Click Here For Your Free Guide Cellectis Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks70th Percentile Overall ScoreCLLS MarketRank™: Cellectis scored higher than 70% of companies evaluated by MarketBeat, and ranked 302nd out of 986 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCellectis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCellectis has only been the subject of 1 research reports in the past 90 days.Read more about Cellectis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cellectis are expected to decrease in the coming year, from ($0.46) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectis is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectis is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellectis has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cellectis' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.28% of the outstanding shares of Cellectis have been sold short.Short Interest Ratio / Days to CoverCellectis has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectis has recently decreased by 54.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCellectis does not currently pay a dividend.Dividend GrowthCellectis does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.28% of the outstanding shares of Cellectis have been sold short.Short Interest Ratio / Days to CoverCellectis has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectis has recently decreased by 54.96%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.43 News SentimentCellectis has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Cellectis this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CLLS on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cellectis insiders have not sold or bought any company stock.Percentage Held by Insiders16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cellectis' insider trading history. Receive CLLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter. Email Address CLLS Stock News HeadlinesCellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.comNovember 13 at 3:09 AM | americanbankingnews.comPromising Partnership and Pipeline Propel Cellectis SA to a Buy RatingNovember 8, 2024 | markets.businessinsider.comEver heard of this 8-day bitcoin profit window? Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.November 13, 2024 | DTI (Ad)Cellectis S.A. (NASDAQ:CLLS) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comCellectis SA: Strategic Advancements and Financial Strengths Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comCellectis price target lowered to $5 from $7 at BarclaysNovember 7, 2024 | markets.businessinsider.comCellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual MeetingNovember 5, 2024 | globenewswire.comCellectis S.A. (CLLS) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comSee More Headlines CLLS Stock Analysis - Frequently Asked Questions How have CLLS shares performed this year? Cellectis' stock was trading at $3.08 at the start of the year. Since then, CLLS stock has decreased by 35.7% and is now trading at $1.98. View the best growth stocks for 2024 here. How were Cellectis' earnings last quarter? Cellectis S.A. (NASDAQ:CLLS) released its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.03. The biotechnology company had revenue of $18.05 million for the quarter, compared to analysts' expectations of $5 million. Cellectis had a negative net margin of 234.39% and a negative trailing twelve-month return on equity of 74.55%. When did Cellectis IPO? Cellectis (CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are Cellectis' major shareholders? Top institutional investors of Cellectis include Baillie Gifford & Co. (1.25%), Principal Financial Group Inc. (0.74%) and First Affirmative Financial Network (0.04%). How do I buy shares of Cellectis? Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cellectis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectis investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU) and Alibaba Group (BABA). Company Calendar Last Earnings11/04/2024Today11/13/2024Fiscal Year End12/31/2024Next Earnings (Estimated)5/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLLS CUSIPN/A CIK1627281 Webwww.cellectis.com Phone(318) 169-1600Fax33-1-81-69-16-06Employees290Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+259.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,060,000.00 Net Margins-234.39% Pretax Margin-235.80% Return on Equity-74.55% Return on Assets-22.65% Debt Debt-to-Equity Ratio0.48 Current Ratio1.78 Quick Ratio1.78 Sales & Book Value Annual Sales$29.07 million Price / Sales3.73 Cash FlowN/A Price / Cash FlowN/A Book Value$2.33 per share Price / Book0.84Miscellaneous Outstanding Shares55,584,000Free Float46,463,000Market Cap$108.39 million OptionableOptionable Beta3.10 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:CLLS) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.